EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP

Claus Bachert, Asif H Khan, Wytske J Fokkens, Claire Hopkins, Philippe Gevaert, Joseph K Han, Peter W Hellings, Stella E Lee, Jérôme Msihid, Scott Nash, Harry Sacks, Juby A Jacob-Nara und 2 weitere

Journal of Allergy and Clinical Immunology · 2024

DOI: 10.1016/j.jaci.2024.07.026 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024. Verfasst von Claus Bachert und 13 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Münster, Münster, Germany; First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: claus.bach…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Nasal Polyps, Sinusitis, Rhinitis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals Inc, Sanofi US.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Responder analyses of SINUS phase 3 study data have shown clinically meaningful improvements across multiple outcomes of treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with dupilumab. OBJECTIVE: Our aim was to gain a better understanding of dynamics of the response to dupilumab over 52 weeks. METHODS: We used data from the SINUS-52 (ClinicalTrials.gov identifier NCT02898454) intention-to-treat population to perform a post hoc analysis of patients with severe CRSwNP who had received dupilumab, 300 mg once every 2 weeks, or placebo. Response, which was defined as an improvement from baseline of at least 1 point in Nasal Polyp Score (NPS), nasal congestion (NC) score, and loss of smell (LoS) score, as well as an improvement of at least 8.9 points on the 22-Item Sino-Nasal Outcome Test (SNOT-22), was assessed for rapidity, maintenance, and durability. RESULTS: The study included 303 patients (150 of whom received dupilumab and 153 of whom received placebo). For each outcome measure, a greater proportion of patients achieved a first response by week 16 (rapidity) with dupilumab versus with placebo; NPS, 75.3% versus 39.2%; NC score, 60.0% versus 24.2%; LoS score, 60.7% versus 15.7%; and SNOT-22 score, 83.3% versus 66.0%, respectively. Of those patients given dupilumab who had a response by week 16, more than 80% maintained their response at week 52 (maintenance). Over 52 weeks, greater proportions of those patients given dupilumab than patients given placebo were responders on at least 80% of time points: NPS, 46.7% versus 2.6%; NC score, 46.7% versus 9.2%; LoS score, 47.3% versus 3.9%; and SNOT-22 score, 62.0% versus 21.6%, respectively (durability). CONCLUSION: Most patients with CRSwNP achieve clinically meaningful responses to dupilumab by week 16, and most such patients in our study had maintenance and durability of response with continued treatment over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNasal PolypsSinusitisRhinitisHumansMaleFemaleMiddle AgedAdultChronic DiseaseTreatment OutcomeDouble-Blind MethodAged

Stichwörter der Autor:innen

Biologic therapySINUS-52chronic rhinosinusitis with nasal polypsdupilumabresponder analysis

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University Hospital of Münster, Münster, Germany; First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: claus.bachert@ukmuenster.de.
  • Sanofi, Bridgewater, NJ.
  • Amsterdam University Medical Centres, Location AMC, Amsterdam, The Netherlands.
  • King's College London, London, United Kingdom.
  • Ghent University, Ghent, Belgium.
  • Eastern Virginia Medical School, Norfolk, Va.

Förderung

  • Regeneron Pharmaceuticals Inc
  • Sanofi US

Zitieren

APA

Bachert, C., Khan, A. H., Fokkens, W. J., Hopkins, C., Gevaert, P., Han, J. K., Hellings, P. W., Lee, S. E., Msihid, J., Nash, S., Sacks, H., Jacob-Nara, J. A., Deniz, Y., & Rowe, P. J. (2024). Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.07.026

Vancouver

Bachert C, Khan AH, Fokkens WJ, Hopkins C, Gevaert P, Han JK, et al. Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP. Journal of Allergy and Clinical Immunology. 2024. doi:10.1016/j.jaci.2024.07.026

BibTeX
@article{Bachert2024,
  author = {Bachert, Claus and Khan, Asif H and Fokkens, Wytske J and Hopkins, Claire and Gevaert, Philippe and Han, Joseph K and Hellings, Peter W and Lee, Stella E and Msihid, Jérôme and Nash, Scott and Sacks, Harry and Jacob-Nara, Juby A and Deniz, Yamo and Rowe, Paul J},
  title = {Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2024},
  doi = {10.1016/j.jaci.2024.07.026}
}
Kostenlos starten →